Immutep Limited (IMMP), a clinical-stage biotechnology company specializing in LAG-3 immunotherapies, announced on Wednesday the completion of patient enrolment in the investigator-initiated EFTISARC-NEO Phase II trial.
The trial is designed to evaluate eftilagimod alpha or efti in combination with radiotherapy and KEYTRUDA or pembrolizumab in patients with resectable soft tissue sarcoma or STS.
EFTISARC-NEO is being conducted by the Maria Sklodowska-Curie National Research Institute of Oncology or MSCNRIO in Warsaw, Poland, and has successfully reached its target enrolment of 40 patients.
The trial aims to assess the safety and efficacy of the triple combination therapy in the neoadjuvant setting for STS patients.
Preliminary data, presented at the Connective Tissue Oncology Society or CTOS Annual Meeting in November 2024, indicated a significant increase in tumour hyalinization/fibrosis, a potential indicator of improved survival with the combination treatment compared to radiotherapy alone.
This early endpoint showed a greater than three-fold improvement, with a median 50% hyalinization/fibrosis rate, compared to the historical median of 15% from radiotherapy alone.
The treatment was well tolerated, with no grade =3 toxicities related to efti and pembrolizumab.
Data updates from the EFTISARC-NEO trial are expected in 2025, marking a crucial step in Immutep's efforts to advance novel immunotherapy treatments for cancer.
Currently, IMMP is trading at $1.97 up by 3.40%.
For comments and feedback: editorial@rttnews.com